Advancing Next-Generation Therapeutics with Programmable Biology: Disrupting the GLP-1 Paradigm for Enhanced Treatment Diversity at Scale
- Utilizing genetic code expansion and engineered translation for the incorporation of non-canonical amino acids (ncAAs) for creating new-to-nature biotherapeutics; enabling drug candidates with improved stability, efficacy, and novel mechanisms of action beyond traditional incretin agonism
- Exploring how sustainable biomanufacturing is strategically important to overcome the high cost and inefficiency of existing chemical peptide synthesis methods, ensuring that next-generation peptide therapeutics can meet massive global demand at partner-grade quality and industry-scale titres
- Prioritizing platform technologies in commercialization strategies that enable rapid, cost-effective scale-up and yield differentiated value, moving the field past dose-optimization of existing drugs toward wholly novel, patient-focused treatments